Literature for peptidase S01.214: coagulation factor IXa

Summary Gene structure Alignment Tree Sequences Sequence features Distribution Structure Literature Substrates Pharma

(Topics flags: A Assay, S Structure, T Target, K Knockout, E Expression, V Review, M Mutation, I Inhibitor, U Therapeutic. To select only the references relevant to a single topic, click the link above. See explanation.)

2026

de Vries,P.S. Insights from a genome-wide association study of factor IX activity J Thromb Haemost (2026) 24, 381-383. PubMed Europe PubMed DOI
Shi,X., Shi,M., Fu,J., Lv,X., Zhang,L., Yuan,Q., Zhao,L. and Zhang,B. Structure-activity relationship of a potent anti-FXase and antithrombotic chondroitin sulfate-dermatan sulfate hybrid bearing 2,3-O-sulfated motifs from Anthenoides laevigatus Carbohydr Polym (2026) 375, 124752-124752. PubMed Europe PubMed DOI

2025

Bozhko,A.A. and Panteleev,M.A. A mathematical model for activated platelet-dependent activation of coagulation factor X by factor IXa Comput Biol Med (2025) 192, 110263-110263. PubMed Europe PubMed DOI

2024

Bos,M.H.A., van Diest,R.E. and Monroe,D.M. Blood coagulation factor IX: structural insights impacting hemophilia B therapy Blood (2024) 144, 2198-2210. PubMed Europe PubMed DOI V
Coyle,C.W., Knight,K.A., Brown,H.C., George,S.N., Denning,G., Branella,G.M., Childers,K.C., Spiegel,P.C., Spencer,H.T. and Doering,C.B. Humanization and functional characterization of enhanced coagulation factor IX variants identified through ancestral sequence reconstruction J Thromb Haemost (2024) 22, 633-644. PubMed Europe PubMed DOI PMC EPMC
Fang,L., Jin,J., Zhang,Z., Yu,S., Tian,C., Luo,F., Long,M., Zuo,H. and Lou,S. Antidote-controlled DNA aptamer modulates human factor IXa activity Bioorg Chem (2024) 148, 107463-107463. PubMed Europe PubMed DOI
Kolyadko,V.N., Layzer,J.M., Perry,K., Sullenger,B.A. and Krishnaswamy,S. An RNA aptamer exploits exosite-dependent allostery to achieve specific inhibition of coagulation factor IXa Proc Natl Acad Sci U S A (2024) 121, e2401136121-e2401136121. PubMed Europe PubMed DOI PMC EPMC
Ma,Y., Li,Y., Sun,J., Liang,Q., Wu,R., Ding,Q. and Dai,J. Complete F9 Gene Deletion, Duplication, and Triplication Rearrangements: Implications for Factor IX Expression and Clinical Phenotypes Thromb Haemost (2024) 124, 374-385. PubMed Europe PubMed DOI
Misenheimer,T.M., Lasarev,M.R., Kumfer,K.T., Sheehan,J.P. and Schwartz,B.S. A novel factor IXa-specific enzyme-linked immunosorbent assay detects factor IXa in human plasma Res Pract Thromb Haemost (2024) 8, 102338-102338. PubMed Europe PubMed DOI PMC EPMC
Oda,A., Takeyama,M., Kitazawa,T. and Nogami,K. The emicizumab-bridged ternary complex with activated factor IX and factor X evaluated by fluorescence resonance energy transfer Thromb Res (2024) 237, 108-111. PubMed Europe PubMed DOI
Ortel,T.L. Introduction to a review series on von Willebrand factor, factor VIII, and factor IX Blood (2024) 144, 2157-2158. PubMed Europe PubMed DOI
Park,B.H., Yun,H. and Jeong,H.J. Soluble expression of recombinant coagulation factor IX protein using Escherichia coli Biochem Biophys Rep (2024) 38, 101714-101714. PubMed Europe PubMed DOI PMC EPMC
Soloveva,P.A., Podoplelova,N.A. and Panteleev,M.A. Binding of coagulation factor IXa to procoagulant platelets revisited: Low affinity and interactions with other factors Biochem Biophys Res Commun (2024) 720, 150099-150099. PubMed Europe PubMed DOI
Wei,X., Zhang,H., Chen,W., Zhang,J. and Dai,J. A study of recurrent life-threatening thrombosis accompanied with the duplication of the factor IX gene Thromb J (2024) 22, 1-1. PubMed Europe PubMed DOI PMC EPMC

2023

Abraham,S. and Duncan,E.M. A Review of Factor VIII and Factor IX Assay Methods for Monitoring Extended Half-Life Products in Hemophilia A and B Methods Mol Biol (2023) 2663, 569-588. PubMed Europe PubMed DOI V
Desage,S., Leuci,A., Enjolras,N., Holle,L.A., Singh,S., Delavenne,X., Wolberg,A.S., Biswas,A. and Dargaud,Y. Characterization of a recombinant factor IX molecule fused to coagulation factor XIII-B subunit Haemophilia (2023) 29, 1483-1489. PubMed Europe PubMed DOI
Ge,R., Wang,C., Liu,J., Jiang,H., Jiang,X. and Liu,Z. A Novel Tumor-Promoting Role for Nuclear Factor IX in Glioblastoma Is Mediated through Transcriptional Activation of GINS1 Mol Cancer Res (2023) 21, 189-198. PubMed Europe PubMed DOI K
Turkut Tan,T., Pariltay,E., Avci Durmusaliogu,E., Isik,E., Cogulu,O., Kavakli,K. and Atik,T. A unique case of thrombophilia: the role of F9 gene duplication and increased factor IX activity in cerebral venous thrombosis J Thromb Haemost (2023) 21, 2913-2916. PubMed Europe PubMed DOI
Wang,R., Jiang,S., Wang,X., Wei,D., Xu,Q. and Wu,W. Structural and functional exploration of three newly identified coagulation factor IX mutations in Chinese hemophilia B patients Int J Hematol (2023) 118, 201-209. PubMed Europe PubMed DOI
Yoon,H.J., Kundu,S. and Wu,S. Molecular Dynamics Simulation Study of the Selective Inhibition of Coagulation Factor IXa over Factor Xa Molecules (2023) 28 PubMed Europe PubMed DOI PMC EPMC

2022

Afosah,D.K., Ofori,E., Mottamal,M. and Al-Horani,R.A. Factor IX(a) inhibitors: an updated patent review (2003-present) Expert Opin Ther Pat (2022) , 1-20. PubMed Europe PubMed DOI
Beauglehole,A.C., Roche Recinos,D., Pegg,C.L., Lee,Y.Y., Turnbull,V., Herrmann,S., Marcellin,E., Howard,C.B. and Schulz,B.L. Recent advances in the production of recombinant factor IX: bioprocessing and cell engineering Crit Rev Biotechnol (2022) , 1-19. PubMed Europe PubMed DOI V
Majumder,R. Phosphatidylserine Regulation of Coagulation Proteins Factor IXa and Factor VIIIa J Membr Biol (2022) 255, 733-737. PubMed Europe PubMed DOI V
Sato,R., Watanabe,K., Kamata,R. and Takeda,K. Development of a sandwich enzyme-linked immunosorbent assay (ELISA) to quantify gamma-glutamyl-carboxylated clotting factor IX and assess redox susceptibility of anticoagulant chemicals J Vet Med Sci (2022) 84, 804-808. PubMed Europe PubMed DOI PMC EPMC
Vatandoost,J. and Bos,M.H.A. Effect of prepropeptide replacement on gamma-carboxylation and activity of recombinant coagulation factor IX Biotechnol Lett (2022) 44, 975-984. PubMed Europe PubMed DOI

2021

Freato,N., van Alphen,F.P.J., Boon-Spijker,M., van den Biggelaar,M., Meijer,A.B., Mertens,K. and Ebberink,E.H.T.M. Probing activation-driven changes in coagulation factor IX by mass spectrometry J Thromb Haemost (2021) PubMed Europe PubMed DOI
Kearney,K.J., Butler,J., Posada,O.M., Wilson,C., Heal,S., Ali,M., Hardy,L., Ahnstrom,J., Gailani,D., Foster,R., Hethershaw,E., Longstaff,C. and Philippou,H. Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI Proc Natl Acad Sci U S A (2021) 118 PubMed Europe PubMed DOI
Knight,K.A., Coyle,C.W., Radford,C.E., Parker,E.T., Fedanov,A., Shields,J.M., Szlam,F., Purchel,A., Chen,M., Denning,G., Sniecinski,R.M., Lollar,P., Spencer,H.T., Gaucher,E.A. and Doering,C.B. Identification of coagulation factor IX variants with enhanced activity through ancestral sequence reconstruction Blood Adv (2021) 5, 3333-3343. PubMed Europe PubMed DOI
Kundu,S. and Wu,S. A Structure Based Study of Selective Inhibition of Factor IXa over Factor Xa Molecules (2021) 26 PubMed Europe PubMed DOI PMC EPMC
Larson,E.A., Larson,H.J., Taylor,J.A. and Klein,R.F. Deletion of Coagulation Factor IX Compromises Bone Mass and Strength: Murine Model of Hemophilia B (Christmas Disease) Calcif Tissue Int (2021) PubMed Europe PubMed DOI
Lombardi,S., Aaen,K.H., Nilsen,J., Ferrarese,M., Gjolberg,T.T., Bernardi,F., Pinotti,M., Andersen,J.T. and Branchini,A. Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity Br J Haematol (2021) PubMed Europe PubMed DOI
Miller,C.H. The Clinical Genetics of Hemophilia B (Factor IX Deficiency) Appl Clin Genet (2021) 14, 445-454. PubMed Europe PubMed DOI PMC EPMC
Robinson,M.M., George,L.A., Carr,M.E., Samelson-Jones,B.J., Arruda,V.R., Murphy,J.E., Rybin,D., Rupon,J., High,K.A. and Tiefenbacher,S. Factor IX Assay Discrepancies in the Setting of Liver Gene Therapy Using a Hyperfunctional Variant Factor IX-Padua J Thromb Haemost (2021) PubMed Europe PubMed DOI
Samelson-Jones,B.J., Finn,J.D., Raffini,L.J., Merricks,E.P., Camire,R.M., Nichols,T.C. and Arruda,V.R. Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants Blood Adv (2021) 5, 1324-1332. PubMed Europe PubMed DOI PMC EPMC
Wu,W., Xiao,L., Wu,X., Xie,X., Li,P., Chen,C., Zheng,Z., Ai,J., Valencia,A., Dong,B., Ding,Q., Dong,B. and Wang,X. Factor IX alteration p.Arg338Gln (FIX Shanghai) potentiates FIX clotting activity and causes thrombosis Haematologica (2021) 26, 568-585. PubMed Europe PubMed DOI M
Yin,R. and Liu,C. Human coagulation factor IX: a systematic review of its characteristics Blood Coagul Fibrinolysis (2021) PubMed Europe PubMed DOI

2020

Nichols,T.C., Levy,H., Merricks,E.P., Raymer,R.A. and Lee,M.L. Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa PLoS ONE (2020) 15, e0240896-e0240896. PubMed Europe PubMed DOI PMC EPMC
Noubouossie,D.F., Henderson,M.W., Mooberry,M., Ilich,A., Ellsworth,P., Piegore,M., Skinner,S.C., Pawlinski,R., Welsby,I., Renne,T., Hoffman,M., Monroe,D.M. and Key,N.S. Red blood cell microvesicles activate the contact system leading to factor IX activation via two independent pathways Blood (2020) 135, 755-765. PubMed Europe PubMed DOI
Pegg,C.L., Zacchi,L.F., Recinos,D.R., Howard,C.B. and Schulz,B.L. Identification of novel glycosylation events on human serum-derived factor IX Glycoconj J (2020) PubMed Europe PubMed DOI
Shima,M. Bispecific Antibodies and Advances in Non-Gene Therapy Options in Hemophilia Res Pract Thromb Haemost (2020) 4, 446-454. PubMed Europe PubMed DOI PMC EPMC
Sousa Bomfim,A., Correa de Freitas,M.C., Picanco Castro,V., Abreu Soares Neto,M., Padua,R., Covas,D.T. and Sousa Russo,E.M. Generation of hyperfunctional recombinant human factor IX variants expressed in human cell line SK-Hep-1 Biotechnol Lett (2020) PubMed Europe PubMed DOI
Takeyama,M., Nogami,K., Matsumoto,T., Noguchi-Sasaki,M., Kitazawa,T. and Shima,M. An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A J Thromb Haemost (2020) 18, 825-833. PubMed Europe PubMed DOI

2019

Alexaki,A., Hettiarachchi,G.K., Athey,J.C., Katneni,U.K., Simhadri,V., Hamasaki-Katagiri,N., Nanavaty,P., Lin,B., Takeda,K., Freedberg,D., Monroe,D., McGill,J.R., Peters,R., Kames,J.M., Holcomb,D.D., Hunt,R.C., Sauna,Z.E., Gelinas,A., Janjic,N., DiCuccio,M., Bar,H., Komar,A.A. and Kimchi-Sarfaty,C. Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies Sci Rep (2019) 9, 15449-15449. PubMed Europe PubMed DOI PMC EPMC E
Bahrami,S., Ghaffari,M. and Zomorodipour,A. Production of recombinant human factor IX by propeptide modification in Drosophila S2 cell line Biotechnol Lett (2019) 41, 347-355. PubMed Europe PubMed DOI E
Meireles,M.R., Bragatte,M.A.S., Bandinelli,E., Salzano,F.M. and Vieira,G.F. A new in silico approach to investigate molecular aspects of factor IX missense causative mutations and their impact on the hemophilia B severity Hum Mutat (2019) 40, 706-715. PubMed Europe PubMed DOI M
Saini,S., Croteau,S.E., Horling,F.M. and Dunn,A.L. Factor IX inhibitors: clinical and laboratory profiles of two patients with severe haemophilia B Haemophilia (2019) 25, e126-e126. PubMed Europe PubMed DOI M
Spronck,E.A., Liu,Y.P., Lubelski,J., Ehlert,E., Gielen,S., Montenegro-Miranda,P., de Haan,M., Nijmeijer,B., Ferreira,V., Petry,H. and van Deventer,S.J. Enhanced factor IX activity following administration of AAV5-R338L "Padua" factor IX versus AAV5 WT human factor IX in NHPs Mol Ther Methods Clin Dev (2019) 15, 221-231. PubMed Europe PubMed DOI PMC EPMC M
Vadivel,K., Schreuder,H.A., Liesum,A., Schmidt,A.E., Goldsmith,G. and Bajaj,S.P. Sodium-site in serine protease domain of human coagulation factor IXa: evidence from the crystal structure and molecular dynamics simulations study J Thromb Haemost (2019) 17, 574-584. PubMed Europe PubMed DOI S
Vatandoost,J. and Bos,M.H.A. Improved activity and expression of recombinant human factor IX by propeptide engineering Daru (2019) 27, 653-660. PubMed Europe PubMed DOI E U
Wang,X., Gao,L., Shen,N., Liu,A., Lu,Y. and Hu,Q. Mutation of factor IX Cys178 is intolerant and may cause severe hemophilia B Thromb Res (2019) 183, 108-110. PubMed Europe PubMed DOI M
Xie,C., Wang,Z., Su,Y., Wang,J. and Shen,W.C. Discovery of an orally effective factor IX-transferrin fusion protein for hemophilia B Int J Mol Sci (2019) 21 PubMed Europe PubMed DOI

2018

Collins,P.W., Quon,D.V.K., Makris,M., Chowdary,P., Kempton,C.L., Apte,S.J., Ramanan,M.V., Hay,C.R.M., Drobic,B., Hua,Y., Babinchak,T.J. and Gomperts,E.D. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients Haemophilia (2018) 24, 104-112. PubMed Europe PubMed DOI U
Kershaw,G.W., Dissanayake,K., Chen,V.M. and Khoo,T.L. Evaluation of chromogenic factor IX assays by automated protocols Haemophilia (2018) 24, 492-501. PubMed Europe PubMed DOI A
Kovnir,S.V., Orlova,N.A., Shakhparonov,M.I., Skryabin,K.G., Gabibov,A.G. and Vorobiev,I.I. A highly productive CHO cell line secreting human blood clotting factor IX Acta Naturae (2018) 10, 51-65. PubMed Europe PubMed PMC EPMC E
Le Quellec,S., Enjolras,N., Perot,E., Girard,J., Negrier,C. and Dargaud,Y. Fusion of factor IX to factor XIII-B sub-unit improves the pharmacokinetic profile of factor IX Thromb Haemost (2018) 118, 2053-2063. PubMed Europe PubMed DOI E U
Miesbach,W., Meijer,K., Coppens,M., Kampmann,P., Klamroth,R., Schutgens,R., Tangelder,M., Castaman,G., Schwable,J., Bonig,H., Seifried,E., Cattaneo,F., Meyer,C. and Leebeek,F.W.G. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B Blood (2018) 131, 1022-1031. PubMed Europe PubMed DOI U
Perez Botero,J., Coon,L.M., Majerus,J.A., Chen,D. and Pruthi,R.K. Factor IX gene (F9) genotyping trends and spectrum of mutations identified: a reference laboratory experience Semin Thromb Hemost (2018) 44, 287-292. PubMed Europe PubMed DOI M
Vandendriessche,T. and Chuah,M.K. Hyperactive factor IX Padua: a game-changer for hemophilia gene therapy Mol Ther (2018) 26, 14-16. PubMed Europe PubMed DOI M
Vatandoost,J. and Zarei Sani,O. Effect of propeptide amino acid substitution in gamma-carboxylation, activity and expression of recombinant human coagulation factor IX Biotechnol Prog (2018) 34, 515-520. PubMed Europe PubMed DOI E
Weber,A., Engelmaier,A., Voelkel,D., Pachlinger,R., Scheiflinger,F., Monahan,P.E. and Rottensteiner,H. Development of methods for the selective measurement of the single amino acid exchange variant coagulation factor IX Padua Mol Ther Methods Clin Dev (2018) 10, 29-37. PubMed Europe PubMed DOI PMC EPMC A M

2017

Branchini,A., Ferrarese,M., Campioni,M., Castaman,G., Mari,R., Bernardi,F. and Pinotti,M. Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations Blood (2017) 129, 2303-2307. PubMed Europe PubMed DOI U
George,L.A., Sullivan,S.K., Giermasz,A., Rasko,J.E.J., Samelson-Jones,B.J., Ducore,J., Cuker,A., Sullivan,L.M., Majumdar,S., Teitel,J., McGuinn,C.E., Ragni,M.V., Luk,A.Y., Hui,D., Wright,J.F., Chen,Y., Liu,Y., Wachtel,K., Winters,A., Tiefenbacher,S., Arruda,V.R., van der Loo,J.C.M., Zelenaia,O., Takefman,D., Carr,M.E., Couto,L.B., Anguela,X.M. and High,K.A. Hemophilia B gene therapy with a high-specific-activity factor IX variant N Engl J Med (2017) 377, 2215-2227. PubMed Europe PubMed DOI
Lenting,P.J., Denis,C.V. and Christophe,O.D. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood (2017) 130, 2463-2468. PubMed Europe PubMed DOI
Lillicrap,D. FIX It in One Go: enhanced factor IX gene therapy for hemophilia B Cell (2017) 171, 1478-1480. PubMed Europe PubMed DOI U
Ramaswamy,S., Tonnu,N., Tachikawa,K., Limphong,P., Vega,J.B., Karmali,P.P., Chivukula,P. and Verma,I.M. Systemic delivery of factor IX messenger RNA for protein replacement therapy Proc Natl Acad Sci U S A (2017) 114, E1941-E1950. PubMed Europe PubMed DOI U
Sakurada,I., Endo,T., Hikita,K., Hirabayashi,T., Hosaka,Y., Kato,Y., Maeda,Y., Matsumoto,S., Mizuno,T., Nagasue,H., Nishimura,T., Shimada,S., Shinozaki,M., Taguchi,K., Takeuchi,K., Yokoyama,T., Hruza,A., Reichert,P., Zhang,T., Wood,H.B., Nakao,K. and Furusako,S. Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors Bioorg Med Chem Lett (2017) 27, 2622-2628. PubMed Europe PubMed DOI I
Simhadri,V.L., Hamasaki-Katagiri,N., Lin,B.C., Hunt,R., Jha,S., Tseng,S.C., Wu,A., Bentley,A.A., Zichel,R., Lu,Q., Zhu,L., Freedberg,D.I., Monroe,D.M., Sauna,Z.E., Peters,R., Komar,A.A. and Kimchi-Sarfaty,C. Single synonymous mutation in factor IX alters protein properties and underlies haemophilia B J Med Genet (2017) 54, 338-345. PubMed Europe PubMed DOI M

2016

Ankrom,W., Wood,H.B., Xu,J., Geissler,W., Bateman,T., Chatterjee,M.S., Feng,K.I., Metzger,J.M., Strapps,W.R., Tadin-Strapps,M., Seiffert,D. and Andre,P. Preclinical and translational evaluation of coagulation factor IXa as a novel therapeutic target Pharmacol Res Perspect (2016) 4, e00207-e00207. PubMed Europe PubMed DOI PMC EPMC T
Choudhury,S., Plautz,W.E., Zacarias,C. and Majumder,R. Mini-review on "A novel one-step purification of mouse factor IX" J Rare Dis Res Treat (2016) 1, 8-10. PubMed Europe PubMed PMC EPMC V U
do Amaral,R.L., de Sousa Bomfim,A., de Abreu-Neto,M.S., Picanco-Castro,V., de Sousa Russo,E.M., Covas,D.T. and Swiech,K. Approaches for recombinant human factor IX production in serum-free suspension cultures Biotechnol Lett (2016) 38, 385-394. PubMed Europe PubMed DOI E
Kristensen,L.H., Olsen,O.H., Blouse,G.E. and Brandstetter,H. Releasing the brakes in coagulation factor IXa by co-operative maturation of the substrate-binding site Biochem J (2016) 473, 2395-2411. PubMed Europe PubMed DOI
Monroe,D.M., Jenny,R.J., Van Cott,K.E., Buhay,S. and Saward,L.L. Characterization of IXINITY(R) (trenonacog alfa), a recombinant factor IX with primary sequence corresponding to the threonine-148 polymorph Adv Hematol (2016) 2016, 7678901-7678901. PubMed Europe PubMed DOI PMC EPMC
Negrier,C., Abdul Karim,F., Lepatan,L.M., Lienhart,A., Lopez-Fernandez,M.F., Mahlangu,J., Pabinger,I., Li,Y., Wolko,D., Voigt,C., Jacobs,I. and Santagostino,E. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery Haemophilia (2016) 22, e259-e266. PubMed Europe PubMed DOI U
Pilli,V.S., Plautz,W.E., Monroe DM 3rd and Majumder,R. A novel one-step purification of mouse factor IX Thromb Res (2016) 139, 125-126. PubMed Europe PubMed DOI
Santagostino,E. Transforming the treatment for hemophilia B patients: update on the clinical development of recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP) Thromb Res (2016) 141 Suppl 3, S5-S8. PubMed Europe PubMed DOI U
Toby,G.G., Liu,T., Buyue,Y., Zhang,X., Bitonti,A.J., Pierce,G.F., Sommer,J.M., Jiang,H. and Peters,R.T. Recombinant factor IX Fc fusion protein maintains full procoagulant properties and exhibits prolonged efficacy in hemophilia B mice PLoS ONE (2016) 11, e0148255-e0148255. PubMed Europe PubMed DOI PMC EPMC E
Vatandoost,J. and Bos,M.H. Efficient expression of functional human coagulation factor IX in stably-transfected Drosophila melanogaster S2 cells; comparison with the mammalian CHO system Biotechnol Lett (2016) 38, 1691-1698. PubMed Europe PubMed DOI E

2015

Dumont,J.A., Loveday,K.S., Light,D.R., Pierce,G.F. and Jiang,H. Evaluation of the toxicology, pharmacokinetics, and local tolerance of recombinant factor IX Fc fusion protein in animals Thromb Res (2015) 136, 371-378. PubMed Europe PubMed DOI U
Enjolras,N., Perot,E., Le Quellec,S., Indalecio,A., Girard,J., Negrier,C. and Dargaud,Y. In vivo efficacy of human recombinant factor IX produced by the human hepatoma cell line HuH-7 Haemophilia (2015) 21, e317-e321. PubMed Europe PubMed DOI E U
Khorshidi,S., Zomorodipour,A., Behmanesh,M., Vatandoost,J. and Bos,M.H. Functional expression of the human coagulation factor IX using heterologous signal peptide and propeptide sequences in mammalian cell line Biotechnol Lett (2015) 37, 1773-1781. PubMed Europe PubMed DOI E
Lu,Q., Yang,L., Manithody,C., Wang,X. and Rezaie,A.R. Expression and characterization of Gly-317 variants of factor IX causing variable bleeding in hemophilia B patients Biochemistry (2015) 54, 3814-3821. PubMed Europe PubMed DOI M
Meng,D., Andre,P., Bateman,T.J., Berger,R., Chen,Y.H., Desai,K., Dewnani,S., Ellsworth,K., Feng,D., Geissler,W.M., Guo,L., Hruza,A., Jian,T., Li,H., Metzger,J., Parker,D.L., Reichert,P., Sherer,E.C., Smith,C.J., Sonatore,L.M., Tschirret-Guth,R., Wu,J., Xu,J., Zhang,T., Campeau,L.C., Orr,R., Poirier,M., McCabe-Dunn,J., Araki,K., Nishimura,T., Sakurada,I., Hirabayashi,T. and Wood,H.B. Development of a novel tricyclic class of potent and selective FIXa inhibitors Bioorg Med Chem Lett (2015) 25, 5437-5443. PubMed Europe PubMed DOI S I
Monahan,P.E., Sun,J., Gui,T., Hu,G., Hannah,W.B., Wichlan,D.G., Wu,Z., Grieger,J.C., Li,C., Suwanmanee,T., Stafford,D.W., Booth,C.J., Samulski,J.J., Kafri,T., McPhee,S.W. and Samulski,R.J. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial Hum Gene Ther (2015) 26, 69-81. PubMed Europe PubMed DOI U
Nakamura,Y., Murata,M., Takagi,Y., Kozuka,T., Nakata,Y., Hasebe,R., Takagi,A., Kitazawa,J., Shima,M. and Kojima,T. SVA retrotransposition in exon 6 of the coagulation factor IX gene causing severe hemophilia B Int J Hematol (2015) 102, 134-139. PubMed Europe PubMed DOI M
Parker DL Jr, Walsh,S., Li,B., Kim,E., Sharipour,A., Smith,C., Chen,Y.H., Berger,R., Harper,B., Zhang,T., Park,M., Shu,M., Wu,J., Xu,J., Dewnani,S., Sherer,E.C., Hruza,A., Reichert,P., Geissler,W., Sonatore,L., Ellsworth,K., Balkovec,J., Greenlee,W. and Wood,H.B. Rapid development of two factor IXa inhibitors from hit to lead Bioorg Med Chem Lett (2015) 25, 2321-2325. PubMed Europe PubMed DOI I
Perot,E., Enjolras,N., Le Quellec,S., Indalecio,A., Girard,J., Negrier,C. and Dargaud,Y. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity Thromb Res (2015) 135, 1017-1024. PubMed Europe PubMed DOI E U
Powell,J., Shapiro,A., Ragni,M., Negrier,C., Windyga,J., Ozelo,M., Pasi,J., Baker,R., Potts,J., Li,S., Mei,B., Pierce,G.F. and Robinson,B. Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates Br J Haematol (2015) 168, 113-123. PubMed Europe PubMed DOI U
Turecek,P.L., Abbuhl,B., Tangada,S.D., Chapman,M., Gritsch,H., Rottensteiner,H., Schrenk,G., Mitterer,A., Dietrich,B., Hollriegl,W., Schiviz,A., Horling,F., Reipert,B.M., Muchitsch,E.M., Pavlova,B.G. and Scheiflinger,F. Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes Expert Rev Clin Pharmacol (2015) 8, 163-177. PubMed Europe PubMed DOI
Urasinski,T., Stasyshyn,O., Andreeva,T., Rusen,L., Perina,F.G., Oh,M.S., Chapman,M., Pavlova,B.G., Valenta-Singer,B. and Abbuehl,B.E. Recombinant factor IX (BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial Haemophilia (2015) 21, 196-203. PubMed Europe PubMed DOI U
Zhang,R., Wang,Q., Zhang,L. and Chen,S. Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B Front Med (2015) 9, 90-99. PubMed Europe PubMed DOI E U
Zhang,T., Andre,P., Bateman,T.J., Chen,Y.H., Desai,K., Ellsworth,K., Geissler,W.M., Guo,L., Hruza,A., Jian,T., Meng,D., Parker DL Jr, Qian,X., Reichert,P., Sherer,E.C., Shu,M., Smith,C.J., Sonatore,L.M., Tschirret-Guth,R., Nolting,A.F., Orr,R., Campeau,L.C., Araki,K., Nishimura,T., Sakurada,I. and Wood,H.B. Development of a novel class of potent and selective FIXa inhibitors Bioorg Med Chem Lett (2015) 25, 4945-4949. PubMed Europe PubMed DOI I

2014

Cao,D.H., Liu,X.L., Mu,K., Ma,X.W., Sun,J.L., Bai,X.Z., Lin,C.K. and Jin,C.L. Identification and genetic analysis of a factor IX gene intron 3 mutation in a hemophilia B pedigree in China Turk J Haematol (2014) 31, 226-230. PubMed Europe PubMed DOI M
Ducore,J.M., Miguelino,M.G. and Powell,J.S. Alprolix (recombinant factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B Expert Rev Hematol (2014) 7, 559-571. PubMed Europe PubMed DOI U
Gailani,D., Geng,Y., Verhamme,I., Sun,M.F., Bajaj,S.P., Messer,A. and Emsley,J. The mechanism underlying activation of factor IX by factor XIa Thromb Res (2014) 133 Suppl 1, S48-S51. PubMed Europe PubMed DOI PMC EPMC
Liu,J., Jonebring,A., Hagstrom,J., Nystrom,A.C. and Lovgren,A. Improved expression of recombinant human factor IX by co-expression of GGCX, VKOR and furin Protein J (2014) 33, 174-183. PubMed Europe PubMed DOI E
Mancuso,M.E. GlycoPEGylated factor IX: a new step forward Blood (2014) 124, 3836-3837. PubMed Europe PubMed DOI U
McCue,J., Osborne,D., Dumont,J., Peters,R., Mei,B., Pierce,G.F., Kobayashi,K. and Euwart,D. Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein Haemophilia (2014) 20, e327-e335. PubMed Europe PubMed DOI U
Simhadri,V.L., Hamasaki-Katagiri,N., Tseng,S.C., Bentley,A.A., Zichel,R., Hershko,A.Y., Komar,A.A. and Kimchi-Sarfaty,C. Factor IX oligomerization underlies reduced activity upon disruption of physiological conditions Haemophilia (2014) 20, e157-e163. PubMed Europe PubMed DOI
Venkateswarlu,D. Structural insights into the interaction of blood coagulation co-factor VIIIa with factor IXa: a computational protein-protein docking and molecular dynamics refinement study Biochem Biophys Res Commun (2014) 452, 408-414. PubMed Europe PubMed DOI
Windyga,J., Lissitchkov,T., Stasyshyn,O., Mamonov,V., Rusen,L., Lamas,J.L., Oh,M.S., Chapman,M., Fritsch,S., Pavlova,B.G., Wong,W.Y. and Abbuehl,B.E. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level <=2%) haemophilia B Haemophilia (2014) 20, 15-24. PubMed Europe PubMed DOI U
Windyga,J., Solano Trujillo,M.H. and Hafeman,A.E. BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia B Ther Adv Hematol (2014) 5, 168-180. PubMed Europe PubMed DOI PMC EPMC

2013

Bjorkman,S. Population pharmacokinetics of recombinant factor IX: implications for dose tailoring Haemophilia (2013) 19, 753-757. PubMed Europe PubMed DOI U
Branchini,A., Campioni,M., Mazzucconi,M.G., Biondo,F., Mari,R., Bicocchi,M.P., Bernardi,F. and Pinotti,M. Replacement of the Y450 (c234) phenyl ring in the carboxyl-terminal region of coagulation factor IX causes pleiotropic effects on secretion and enzyme activity FEBS Lett (2013) 587, 3249-3253. PubMed Europe PubMed DOI
Brooks,A.R., Sim,D., Gritzan,U., Patel,C., Blasko,E., Feldman,R.I., Tang,L., Ho,E., Zhao,X.Y., Apeler,H. and Murphy,J.E. Glycoengineered factor IX variants with improved pharmacokinetics and subcutaneous efficacy J Thromb Haemost (2013) 11, 1699-1706. PubMed Europe PubMed DOI U
Franchini,M., Frattini,F., Crestani,S., Sissa,C. and Bonfanti,C. Treatment of hemophilia B: focus on recombinant factor IX Biologics (2013) 7, 33-38. PubMed Europe PubMed DOI PMC EPMC U
Geng,Y., Verhamme,I.M., Sun,M.F., Bajaj,S.P., Emsley,J. and Gailani,D. Analysis of the factor XI variant Arg184Gly suggests a structural basis for factor IX binding to factor XIa J Thromb Haemost (2013) 11, 1374-1384. PubMed Europe PubMed DOI M
Lissitchkov,T., Matysiak,M., Zavilska,K., Laguna,P., Gercheva,L., Antonov,A., Moret,A., Caunedo,P., Aznar,J.A., Woodward,M.K. and Paez,A. Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine(R) ) and a recombinant factor IX (BeneFIX(R) ) in patients with severe haemophilia B Haemophilia (2013) 19, 674-678. PubMed Europe PubMed DOI U
Matafonov,A., Cheng,Q., Geng,Y., Verhamme,I.M., Umunakwe,O., Tucker,E.I., Sun,M.F., Serebrov,V., Gruber,A. and Gailani,D. Evidence for factorIX-independent roles for factorXIa in blood coagulation J Thromb Haemost (2013) 11, 2118-2127. PubMed Europe PubMed DOI K
Monzani,P.S., Sangalli,J.R., de Bem,T.H., Bressan,F.F., Fantinato-Neto,P., Pimentel,J.R., Birgel-Junior,E.H., Fontes,A.M., Covas,D.T. and Meirelles,F.V. Breeding of transgenic cattle for human coagulation factor IX by a combination of lentiviral system and cloning Genet Mol Res (2013) 12, 3675-3688. PubMed Europe PubMed DOI U
Rallapalli,P.M., Kemball-Cook,G., Tuddenham,E.G., Gomez,K. and Perkins,S.J. An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B J Thromb Haemost (2013) 11, 1329-1340. PubMed Europe PubMed DOI M
Ribeiro,D.A., Passos,D.F., Ferraz,H.C. and Castilho,L.R. Anion-exchange purification of recombinant factor IX from cell culture supernatant using different chromatography supports J Chromatogr B Analyt Technol Biomed Life Sci (2013) 938, 111-118. PubMed Europe PubMed DOI U
Yang,L. and Rezaie,A.R. Residues of the 39-loop restrict the plasma inhibitor specificity of factor IXa J Biol Chem (2013) 288, 12692-12698. PubMed Europe PubMed DOI

2012

Buchlis,G., Podsakoff,G.M., Radu,A., Hawk,S.M., Flake,A.W., Mingozzi,F. and High,K.A. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer Blood (2012) 119, 3038-3041. PubMed Europe PubMed DOI U
Marcinkiewicz,M.M., Sinha,D. and Walsh,P.N. Productive recognition of factor IX by factor XIa exosites requires disulfide linkage between heavy and light chains of factor XIa J Biol Chem (2012) 287, 6187-6195. PubMed Europe PubMed DOI
Milanov,P., Ivanciu,L., Abriss,D., Quade-Lyssy,P., Miesbach,W., Alesci,S., Tonn,T., Grez,M., Seifried,E. and Schuttrumpf,J. Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice Blood (2012) 119, 602-611. PubMed Europe PubMed DOI U
Monahan,P.E., Velander,W.H. and Bajaj,S.P. Coagulation factor IXa [ISSN:978-0-12-407742-3] (2012) 3, 2898-2905. DOI
Perez-Garrido,R., Alonso,N., Jimenez-Yuste,V., Haya,S., Zuniga,P., Baques,A., Candela,M., Davoli,M. and Rescia,V. Efficacy of factor IX Grifols((R)) in surgery: experience of an international multicentre retrospective study Haemophilia (2012) 18, e372-e373. PubMed Europe PubMed DOI U
Sayyar,B., Dodd,M., Wen,J., Ma,S., Marquez-Curtis,L., Janowska-Wieczorek,A. and Hortelano,G. Encapsulation of factor IX-engineered mesenchymal stem cells in fibrinogen-alginate microcapsules enhances their viability and transgene secretion J Tissue Eng (2012) 3, 2041731412462018-2041731412462018. PubMed Europe PubMed DOI PMC EPMC U
Serban,M., Skotnicki,A.B., Colovic,M., Jinca,C., Klukowska,A., Laguna,P. and Wolf,D.M. Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B Haemophilia (2012) 18, 175-181. PubMed Europe PubMed DOI U
Sun,Y.L., Chang,Y.S., Lin,Y.S. and Yen,C.H. Pilot production of recombinant human clotting factor IX from transgenic sow milk J Chromatogr B Analyt Technol Biomed Life Sci (2012) 898, 78-89. PubMed Europe PubMed DOI E
Vatandoost,J., Zomorodipour,A., Sadeghizadeh,M., Aliyari,R., Bos,M.H. and Ataei,F. Expression of biologically active human clotting factor IX in Drosophila S2 cells: gamma-carboxylation of a human vitamin K-dependent protein by the insect enzyme Biotechnol Prog (2012) 28, 45-51. PubMed Europe PubMed DOI E

2011

Chang,L.C., Yang,C.Y., Chua,A.C., Lin,Y.J. and Lai,S.M. Sustained release of transgenic human factor IX: preparation, characterization, and in vivo efficacy Mol Pharm (2011) 8, 1767-1774. PubMed Europe PubMed DOI U
Cunha,N.B., Murad,A.M., Ramos,G.L., Maranhao,A.Q., Brigido,M.M., Araujo,A.C., Lacorte,C., Aragao,F.J., Covas,D.T., Fontes,A.M., Souza,G.H., Vianna,G.R. and Rech,E.L. Accumulation of functional recombinant human coagulation factor IX in transgenic soybean seeds Transgenic Res (2011) 20, 841-855. PubMed Europe PubMed DOI E
de Castilho Fernandes,A., Fontes,A., Gonsales,N., Swiech,K., Picanco-Castro,V., Faca,S. and Covas,D. Stable and high-level production of recombinant factor IX in human hepatic cell line Biotechnol Appl Biochem (2011) 58, 243-249. PubMed Europe PubMed DOI E U
Kao,C.Y., Lin,C.N., Yang,Y.L., Hamaguchi,N., Yang,S.J., Shen,M.C., Kao,J.T. and Lin,S.W. Characterisation of factor IX with a glycine-to-valine missense mutation at residue 190 in a patient with severe haemophilia B Thromb Haemost (2011) 105, 616-626. PubMed Europe PubMed DOI M
Keravala,A., Chavez,C.L., Hu,G., Woodard,L.E., Monahan,P.E. and Calos,M.P. Long-term phenotypic correction in factor IX knockout mice by using phiC31 integrase-mediated gene therapy Gene Ther (2011) 18, 842-848. PubMed Europe PubMed DOI U
Lissitchkov,T., Matysiak,M., Zavilska,K., Laguna,P., Gercheva,L., Antonov,A., Cabrera,N., Aznar,J.A., Woodward,M.K. and Paez,A. A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine((R)) , a high-purity factor IX concentrate, in patients with severe haemophilia B Haemophilia (2011) 17, 590-596. PubMed Europe PubMed DOI U
Ostergaard,H., Bjelke,J.R., Hansen,L., Petersen,L.C., Pedersen,A.A., Elm,T., Moller,F., Hermit,M.B., Holm,P.K., Krogh,T.N., Petersen,J.M., Ezban,M., Sorensen,B.B., Andersen,M.D., Agerso,H., Ahmadian,H., Balling,K.W., Christiansen,M.L., Knobe,K., Nichols,T.C., Bjorn,S.E. and Tranholm,M. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide Blood (2011) 118, 2333-2341. PubMed Europe PubMed DOI U
Vaccarino,A., Bazzan,M., Giachino,O., Colagrande,P., Ferraresi,P., Stella,S., Roccatello,D. and Bernardi,F. Factor IX propeptide mutation and life threatening bleeding Thromb Res (2011) 128, 503-504. PubMed Europe PubMed DOI
Wootla,B., Christophe,O.D., Mahendra,A., Dimitrov,J.D., Repesse,Y., Ollivier,V., Friboulet,A., Borel-Derlon,A., Levesque,H., Borg,J.Y., Andre,S., Bayry,J., Calvez,T., Kaveri,S.V. and Lacroix-Desmazes,S. Proteolytic antibodies activate factor IX in patients with acquired hemophilia Blood (2011) 117, 2257-2264. PubMed Europe PubMed DOI

2010

Eikelboom,J.W., Zelenkofske,S.L. and Rusconi,C.P. Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism Arterioscler Thromb Vasc Biol (2010) 30, 382-387. PubMed Europe PubMed DOI T I
Ishiwata,A., Mimuro,J., Mizukami,H., Kashiwakura,Y., Yasumoto,A., Sakata,A., Ohmori,T., Madoiwa,S., Ono,F., Shima,M., Yoshioka,A., Ozawa,K. and Sakata,Y. Mutant macaque factor IX T262A: a tool for hemophilia B gene therapy studies in macaques Thromb Res (2010) 125, 533-537. PubMed Europe PubMed DOI M U
Johnson,D.J., Langdown,J. and Huntington,J.A. Molecular basis of factor IXa recognition by heparin-activated antithrombin revealed by a 1.7-A structure of the ternary complex Proc Natl Acad Sci U S A (2010) 107, 645-650. PubMed Europe PubMed DOI PMC EPMC S
Lin,C.N., Kao,C.Y., Miao,C.H., Hamaguchi,N., Wu,H.L., Shi,G.Y., Liu,Y.L., High,K.A. and Lin,S.W. Generation of a novel factor IX with augmented clotting activities in vitro and in vivo J Thromb Haemost (2010) 8, 1773-1783. PubMed Europe PubMed DOI E U
Lissitchkov,T., Matysiak,M., Zawilska,K., Gercheva,L., Antonov,A., Montanes,M. and Paez,A. An open clinical study assessing the efficacy and safety of factor IX Grifols, a high-purity factor IX concentrate, in patients with severe haemophilia B Haemophilia (2010) 16, 240-246. PubMed Europe PubMed DOI U
Mazetto Bde,M., Orsi,F.L., Siqueira,L.H., de Mello,T.B., de Paula,E.V. and Annichino-Bizzacchi,J.M. Prevalence of factor IX-R338L (factor IX Padua) in a cohort of patients with venous thromboembolism and mild elevation of factor IX levels Thromb Res (2010) 126, e165-e165. PubMed Europe PubMed DOI M
Mizurini,D.M., Francischetti,I.M., Andersen,J.F. and Monteiro,R.Q. Nitrophorin 2, a factor IX(a)-directed anticoagulant, inhibits arterial thrombosis without impairing haemostasis Thromb Haemost (2010) 104, 1116-1123. PubMed Europe PubMed DOI
Monahan,P.E. and Di Paola,J. Recombinant factor IX for clinical and research use Semin Thromb Hemost (2010) 36, 498-509. PubMed Europe PubMed DOI E V
Peters,R.T., Low,S.C., Kamphaus,G.D., Dumont,J.A., Amari,J.V., Lu,Q., Zarbis-Papastoitsis,G., Reidy,T.J., Merricks,E.P., Nichols,T.C. and Bitonti,A.J. Prolonged activity of factor IX as a monomeric Fc fusion protein Blood (2010) 115, 2057-2064. PubMed Europe PubMed DOI U
Sam,M.R., Zomorodipour,A., Shokrgozar,M.A., Ataei,F., Haddad-Mashadrizeh,A. and Amanzadeh,A. Enhancement of the human factor IX expression, mediated by an intron derived fragment from the rat aldolase B gene in cultured hepatoma cells Biotechnol Lett (2010) 32, 1385-1392. PubMed Europe PubMed DOI
Sexton,A., Furmedge,J., Barnes,C., Cheetham,G., Wallace,J. and Savarirayan,R. Clinical significance of two mutations in the factor IX gene in a family with haemophilia B Haemophilia (2010) 16, 374-376. PubMed Europe PubMed DOI M
Verma,D., Moghimi,B., Loduca,P.A., Singh,H.D., Hoffman,B.E., Herzog,R.W. and Daniell,H. Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice Proc Natl Acad Sci U S A (2010) 107, 7101-7106. PubMed Europe PubMed DOI U
Wang,S., Beck,R., Blench,T., Burd,A., Buxton,S., Malic,M., Ayele,T., Shaikh,S., Chahwala,S., Chander,C., Holland,R., Merette,S., Zhao,L., Blackney,M. and Watts,A. Studies of benzothiophene template as potent factor IXa (FIXa) inhibitors in thrombosis J Med Chem (2010) 53, 1465-1472. PubMed Europe PubMed DOI I
Yang,L., Manithody,C., Qureshi,S.H. and Rezaie,A.R. Role of the residues of the 39-loop in determining the substrate and inhibitor specificity of factor IXa J Biol Chem (2010) 285, 28488-28495. PubMed Europe PubMed DOI

2009

Ghosh,K., Quadros,L. and Shetty,S. Spectrum of factor IX gene mutations causing haemophilia B from India Blood Coagul Fibrinolysis (2009) 20, 333-336. PubMed Europe PubMed DOI M
Gui,T., Reheman,A., Ni,H., Gross,P.L., Yin,F., Monroe,D., Monahan,P.E. and Stafford,D.W. Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV J Thromb Haemost (2009) 7, 1843-1851. PubMed Europe PubMed DOI
Hartmann,R., Dockal,M., Kammlander,W., Panholzer,E., Nicolaes,G.A., Fiedler,C., Rosing,J. and Scheiflinger,F. Factor IX mutants with enhanced catalytic activity J Thromb Haemost (2009) 7, 1656-1662. PubMed Europe PubMed DOI E
Simioni,P., Tormene,D., Tognin,G., Gavasso,S., Bulato,C., Iacobelli,N.P., Finn,J.D., Spiezia,L., Radu,C. and Arruda,V.R. X-linked thrombophilia with a mutant factor IX (factor IX Padua) N Engl J Med (2009) 361, 1671-1675. PubMed Europe PubMed DOI M
Zogg,T. and Brandstetter,H. Activation mechanisms of coagulation factor IX Biol Chem (2009) 390, 391-400. PubMed Europe PubMed DOI
Zogg,T. and Brandstetter,H. Structural basis of the cofactor- and substrate-assisted activation of human coagulation factor IXa Structure (2009) 17, 1669-1678. PubMed Europe PubMed DOI S

2008

Chavali,S., Sharma,A., Tabassum,R. and Bharadwaj,D. Sequence and structural properties of identical mutations with varying phenotypes in human coagulation factor IX Proteins (2008) 73, 63-71. PubMed Europe PubMed DOI M
Ding,Y., Wang,J., Tan,W., Chen,Y., Lu,X., Lu,Y., Li,S., Li,H., Wang,L. and Cheng,J. Cloning, sequencing, and analysis of the full-length CDNA of rhesus monkey factor IX Transplant Proc (2008) 40, 2769-2772. PubMed Europe PubMed DOI
Gray,E., Pickering,W., Hockley,J., Rigsby,P., Weinstein,M., Terao,E. and Buchheit,K.H. Collaborative study for the establishment of replacement batches for human coagulation factor IX concentrate reference standards Pharmeuropa Bio (2008) 2008, 19-30. PubMed Europe PubMed A

2007

Cohn,E.F., Zhuo,J., Kelly,M.E. and Chao,H.J. Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer J Thromb Haemost (2007) 5, 1227-1236. PubMed Europe PubMed DOI
Zhang,H., Zhao,L., Chen,Y., Cui,L., Ren,W. and Tang,K. Expression of human coagulation factor IX in transgenic tomato (Lycopersicon esculentum) Biotechnol Appl Biochem (2007) 48, 101-107. PubMed Europe PubMed DOI E

2006

[YEAR:5-9-2006]Fribourg,C., Meijer,A.B. and Mertens,K. The interface between the EGF2 domain and the protease domain in blood coagulation factor IX contributes to factor VIII binding and factor X activation Biochemistry (5-9-2006) 45, 10777-10785. PubMed Europe PubMed DOI
[YEAR:8-8-2006]Rezaie,A.R., Sun,M.F. and Gailani,D. Contributions of basic amino acids in the autolysis loop of factor XIa to serpin specificity Biochemistry (8-8-2006) 45, 9427-9433. PubMed Europe PubMed DOI
Yan,J.B., Wang,S., Huang,W.Y., Xiao,Y.P., Ren,Z.R., Huang,S.Z. and Zeng,Y.T. Transgenic mice can express mutant human coagulation factor IX with higher level of clotting activity Biochem Genet (2006) 44, 349-360. PubMed Europe PubMed DOI E
[YEAR:2-6-2006]Yang,L., Gopalakrishna,K., Manithody,C. and Rezaie,A.R. Expression, purification and characterization of factor IX derivatives using a novel vector system Protein Expr Purif (2-6-2006) 50, 196-202. PubMed Europe PubMed DOI

2005

Begbie,M.E., Mamdani,A., Gataiance,S., Eltringham-Smith,L.J., Bhakta,V., Hortelano,G. and Sheffield,W.P. An important role for the activation peptide domain in controlling factor IX levels in the blood of haemophilia B mice Thromb Haemost (2005) 94, 1138-1147. PubMed Europe PubMed DOI
[YEAR:10-8-2005]Heeb,M.J., Cabral,K.M. and Ruan,L. Down-regulation of factor IXa in the factor Xase complex by protein Z-dependent protease inhibitor J Biol Chem (10-8-2005) 280, 33819-33825. PubMed Europe PubMed DOI
[YEAR:21-9-2005]Shapiro,A.D., Di Paola,J., Cohen,A., Pasi,K.J., Heisel,M.A., Blanchette,V.S., Abshire,T.C., Hoots,W.K., Lusher,J.M., Negrier,C., Rothschild,C. and Roth,D.A. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B Blood (21-9-2005) 105, 518-525. PubMed Europe PubMed DOI

2004

[YEAR:1-11-2004]Batt,D.G., Qiao,J.X., Modi,D.P., Houghton,G.C., Pierson,D.A., Rossi,K.A., Luettgen,J.M., Knabb,R.M., Jadhav,P.K. and Wexler,R.R. 5-Amidinoindoles as dual inhibitors of coagulation factors IXa and Xa Bioorg Med Chem Lett (1-11-2004) 14, 5269-5273. PubMed Europe PubMed DOI I
[YEAR:20-7-2004]Kerschbaumer,R.J., Riedrich,K., Kral,M., Varadi,K., Dorner,F., Rosing,J. and Scheiflinger,F. An antibody specific for coagulation factor IX enhances the activity of the intrinsic factor X-activating complex J Biol Chem (20-7-2004) 279, 40445-40450. PubMed Europe PubMed DOI
[YEAR:16-3-2004]Neuenschwander,P.F. Exosite occupation by heparin enhances the reactivity of blood coagulation factor IXa Biochemistry (16-3-2004) 43, 2978-2986. PubMed Europe PubMed DOI
Schmidt,A.E. and Bajaj,S.P. Coagulation factor IXa [ISSN:0-12-079610-4] (2004) 2, 1655-1659. V
Smallheer,J.M., Alexander,R.S., Wang,J., Wang,S., Nakajima,S., Rossi,K.A., Smallwood,A., Barbera,F., Burdick,D., Luettgen,J.M., Knabb,R.M., Wexler,R.R. and Jadhav,P.K. SAR and factor IXa crystal structure of a dual inhibitor of factors IXa and Xa Bioorg Med Chem Lett (2004) 14, 5263-5267. PubMed Europe PubMed DOI S I

2003

[YEAR:1-3-2003]Ameri,A., Kurachi,S., Sueishi,K., Kuwahara,M. and Kurachi,K. Myocardial fibrosis in mice with overexpression of human blood coagulation factor IX Blood (1-3-2003) 101, 1871-1873. PubMed Europe PubMed DOI
[YEAR:25-6-2003]Josic,D., Hoffer,L. and Buchacher,A. Preparation of vitamin K-dependent proteins, such as clotting factors II, VII, IX and X and clotting inhibitor protein C J Chromatogr B Analyt Technol Biomed Life Sci (25-6-2003) 790, 183-197. PubMed Europe PubMed DOI
Lee,W.H., Zhuang,Q.Y. and Zhang,Y. Cloning and characterization of a blood coagulation factor IX-binding protein from the venom of Trimeresurus stejnegeri Toxicon (2003) 41, 765-772. PubMed Europe PubMed DOI
[YEAR:14-3-2003]Rohlena,J., Kolkman,J.A., Boertjes,R.C., Mertens,K. and Lenting,P.J. Residues Phe342-Asn346 of activated coagulation factor IX contribute to the interaction with low density lipoprotein receptor-related protein J Biol Chem (14-3-2003) 278, 9394-9401. PubMed Europe PubMed DOI
Schmidt,A.E. and Bajaj,S.P. Structure-function relationships in factor IX and factor IXa Trends Cardiovasc Med (2003) 13, 39-45. PubMed Europe PubMed DOI

2002

Bowen,D.J. Haemophilia A and haemophilia B: molecular insights Mol Pathol (2002) 55, 127-144. PubMed Europe PubMed PMC EPMC M V
[YEAR:6-12-2002]Peek,M., Moran,P., Mendoza,N., Wickramasinghe,D. and Kirchhofer,D. Unusual proteolytic activation of pro-hepatocyte growth factor by plasma kallikrein and coagulation factor XIa J Biol Chem (6-12-2002) 277, 47804-47809. PubMed Europe PubMed DOI
[YEAR:20-9-2002]Persson,K.E., Villoutreix,B.O., Thamlitz,A.M., Knobe,K.E. and Stenflo,J. The N-terminal epidermal growth factor-like domain of coagulation factor IX. Probing its functions in the activation of factor IX and factor X with a monoclonal antibody J Biol Chem (20-9-2002) 277, 35616-35624. PubMed Europe PubMed DOI
Persson,K.E.M. Role of the N-terminal EGF module of coagulation factor IX in activation of factors IX and X Scand J Clin Lab Invest (2002) 62, 13-18.
Rodriguez,M.H., Enjolras,N., Plantier,J.L., Rea,M., Leboeuf,M., Uzan,G., Bordet,J.C. and Negrier,C. Expression of coagulation factor IX in a haematopoietic cell line Thromb Haemost (2002) 87, 366-373. PubMed Europe PubMed
Toomey,J.R., Valocik,R.E., Koster,P.F., Gabriel,M.A., McVey,M., Hart,T.K., Ohlstein,E.H., Parsons,A.A. and Barone,F.C. Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke Stroke (2002) 33, 578-585. PubMed Europe PubMed DOI
[YEAR:22-2-2002]Wilkinson,F.H., Ahmad,S.S. and Walsh,P.N. The factor IXa second epidermal growth factor (EGF2) domain mediates platelet binding and assembly of the factor X activating complex J Biol Chem (22-2-2002) 277, 5734-5741. PubMed Europe PubMed DOI
[YEAR:22-2-2002]Wilkinson,F.H., London,F.S. and Walsh,P.N. Residues 88-109 of factor IXa are important for assembly of the factor X activating complex J Biol Chem (22-2-2002) 277, 5725-5733. PubMed Europe PubMed DOI
[YEAR:1-2-2002]Zhong,D., Bajaj,M.S., Schmidt,A.E. and Bajaj,S.P. The N-terminal epidermal growth factor-like domain in factor IX and factor X represents an important recognition motif for binding to tissue factor J Biol Chem (1-2-2002) 277, 3622-3631. PubMed Europe PubMed DOI

2001

Bestmann,L., Zuger,M., Oldenburg,J., Buhler,D. and Maly,F.E. Coagulation factor IX propeptide mutations causing coumarin hypersensitivity: Identification of female alanine-10 valine heterozygotes Thromb Haemost (2001) 85, 567-568. PubMed Europe PubMed
[YEAR:18-9-2001]Hsu,Y.C., Hamaguchi,N., Chang,Y.J. and Lin,S.W. The distinct roles that Gln-192 and Glu-217 of factor IX play in selectivity for macromolecular substrates and inhibitors Biochemistry (18-9-2001) 40, 11261-11269. PubMed Europe PubMed DOI
[YEAR:15-1-2001]Imamura,T., Tanase,S., Hamamoto,T., Potempa,J. and Travis,J. Activation of blood coagulation factor IX by gingipains R, arginine-specific cysteine proteinases from Porphyromonas gingivalis Biochem J (15-1-2001) 353, 325-331. PubMed Europe PubMed DOI PMC EPMC
Melton,L.G., Li,T., Stafford,D.W. and Gabriel,D.A. Location of the platelet binding site in zymogen coagulation factor IX Blood Coagul Fibrinolysis (2001) 12, 237-243. PubMed Europe PubMed DOI
Perera,L., Darden,T.A. and Pedersen,L.G. Modeling human zymogen factor IX Thromb Haemost (2001) 85, 596-603. PubMed Europe PubMed S
[YEAR:15-12-2001]Roth,D.A., Kessler,C.M., Pasi,K.J., Rup,B., Courter,S.G. and Tubridy,K.L. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates Blood (15-12-2001) 98, 3600-3606. PubMed Europe PubMed DOI

2000

[YEAR:3-10-2000]Blostein,M.D., Rigby,A.C., Furie,B.C., Furie,B. and Gilbert,G.E. Amphipathic helices support function of blood coagulation factor IXa Biochemistry (3-10-2000) 39, 12000-12006. PubMed Europe PubMed DOI
[YEAR:7-1-2000]Celie,P.H., Lenting,P.J. and Mertens,K. Hydrophobic contact between the two epidermal growth factor-like domains of blood coagulation factor IX contributes to enzymatic activity J Biol Chem (7-1-2000) 275, 229-234. PubMed Europe PubMed DOI
[YEAR:15-4-2000]Hagstrom,J.N., Couto,L.B., Scallan,C., Burton,M., McCleland,M.L., Fields,P.A., Arruda,V.R., Herzog,R.W. and High,K.A. Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter Blood (15-4-2000) 95, 2536-2542. PubMed Europe PubMed
[YEAR:27-6-2000]Kolkman,J.A. and Mertens,K. Insertion loop 256-268 in coagulation factor IX restricts enzymatic activity in the absence but not in the presence of factor VIII Biochemistry (27-6-2000) 39, 7398-7405. PubMed Europe PubMed DOI
[YEAR:15-9-2000]Kolkman,J.A. and Mertens,K. Surface-loop residue Lys316 in blood coagulation Factor IX is a major determinant for Factor X but not antithrombin recognition Biochem J (15-9-2000) 350, 701-707. PubMed Europe PubMed DOI PMC EPMC
Kurachi,K. and Kurachi,S. Genetic mechanisms of age regulation of blood coagulation: factor IX model Arterioscler Thromb Vasc Biol (2000) 20, 902-906. PubMed Europe PubMed
Makino,Y., Omichi,K., Kuraya,N., Ogawa,H., Nishimura,H., Iwanaga,S. and Hase,S. Structural analysis of N-linked sugar chains of human blood clotting factor IX J Biochem (2000) 128, 175-180. PubMed Europe PubMed
[YEAR:1-2-2000]Samis,J.A., Ramsey,G.D., Walker,J.B., Nesheim,M.E. and Giles,A.R. Proteolytic processing of human coagulation factor IX by plasmin Blood (1-2-2000) 95, 943-951. PubMed Europe PubMed

1999

[YEAR:15-8-1999]Hopfner,K.P., Lang,A., Karcher,A., Sichler,K., Kopetzki,E., Brandstetter,H., Huber,R., Bode,W. and Engh,R.A. Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate binding Structure (15-8-1999) 7, 989-996. PubMed Europe PubMed DOI S
[YEAR:8-10-1999]Kolkman,J.A., Christophe,O.D., Lenting,P.J. and Mertens,K. Surface loop 199-204 in blood coagulation factor IX is a cofactor-dependent site involved in macromolecular substrate interaction J Biol Chem (8-10-1999) 274, 29087-29093. PubMed Europe PubMed DOI
[YEAR:15-4-1999]Kolkman,J.A., Lenting,P.J. and Mertens,K. Regions 301-303 and 333-339 in the catalytic domain of blood coagulation factor IX are factor VIII-interactive sites involved in stimulation of enzyme activity Biochem J (15-4-1999) 339, 217-221. PubMed Europe PubMed DOI PMC EPMC

1998

[YEAR:15-5-1998]Chang,J., Jin,J., Lollar,P., Bode,W., Brandstetter,H., Hamaguchi,N., Straight,D.L. and Stafford,D.W. Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity J Biol Chem (15-5-1998) 273, 12089-12094. PubMed Europe PubMed DOI
[YEAR:1-7-1998]Kundu,R.K., Sangiorgi,F., Wu,L.Y., Kurachi,K., Anderson,W.F., Maxson,R. and Gordon,E.M. Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice Blood (1-7-1998) 92, 168-174. PubMed Europe PubMed K

1997

Bode,W., Brandstetter,H., Mather,T. and Stubbs,M.T. Comparative analysis of haemostatic proteinases: structural aspects of thrombin, factor Xa, factor IXa and protein C Thromb Haemost (1997) 78, 501-511. PubMed Europe PubMed
[YEAR:17-11-1997]Hopfner,K.P., Brandstetter,H., Karcher,A., Kopetzki,E., Huber,R., Engh,R.A. and Bode,W. Converting blood coagulation factor IXa into factor Xa: dramatic increase in amidolytic activity identifies important active site determinants EMBO J (17-11-1997) 16, 6626-6635. PubMed Europe PubMed DOI PMC EPMC
Lin,H.F., Maeda,N., Smithies,O., Straight,D.L. and Stafford,D.W. A coagulation factor IX-deficient mouse model for human hemophilia B Blood (1997) 90, 3962-3966. PubMed Europe PubMed K
[YEAR:28-7-1997]Sturzebecher,J., Kopetzki,E., Bode,W. and Hopfner,K.P. Dramatic enhancement of the catalytic activity of coagulation factor IXa by alcohols FEBS Lett (28-7-1997) 412, 295-300. PubMed Europe PubMed DOI

1996

Boccia,L.M., Lillicrap,D., Newcombe,K. and Mueller,C.R. Binding of the Ets factor GA-binding protein to an upstream site in the factor IX promoter is a critical event in transactivation Mol Cell Biol (1996) 16, 1929-1935. PubMed Europe PubMed PMC EPMC
[YEAR:5-7-1996]Freedman,S.J., Blostein,M.D., Baleja,J.D., Jacobs,M., Furie,B.C. and Furie,B. Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX J Biol Chem (5-7-1996) 271, 16227-16236. PubMed Europe PubMed DOI
Giannelli,F. and Green,P.M. The molecular basis of haemophilia A and B Baillieres Clin Haematol (1996) 9, 211-228. PubMed Europe PubMed DOI
[YEAR:1-1-1996]Giannelli,F., Green,P.M., Sommer,S.S., Poon,M.C., Ludwig,M., Schwaab,R., Reitsma,P.H., Goossens,M., Yoshioka,A. and Brownlee,G.G. Haemophilia B (sixth edition): a database of point mutations and short additions and deletions Nucleic Acids Res (1-1-1996) 24, 103-118. PubMed Europe PubMed DOI PMC EPMC
Sugahara,Y., Catalfamo,J., Brooks,M., Hitomi,E., Bajaj,S.P. and Kurachi,K. Isolation and characterization of canine factor IX Thromb Haemost (1996) 75, 450-455. PubMed Europe PubMed

1995

Brandstetter,H., Bauer,M., Huber,R., Lollar,P. and Bode,W. X-ray structure of clotting factor IXa: Active site and module structure related to Xase activity and hemophilia B Proc Natl Acad Sci U S A (1995) 92, 9796-9800. PubMed Europe PubMed DOI PMC EPMC S
[YEAR:26-9-1995]Freedman,S.J., Furie,B.C., Furie,B. and Baleja,J.D. Structure of the calcium ion-bound gamma-carboxyglutamic acid-rich domain of factor IX Biochemistry (26-9-1995) 34, 12126-12137. PubMed Europe PubMed DOI
[YEAR:23-6-1995]Lenting,P.J., ter Maat,H., Clijsters,P.P., Donath,M.J., Van Mourik,J.A. and Mertens,K. Cleavage at arginine 145 in human blood coagulation factor IX converts the zymogen into a factor VIII binding enzyme J Biol Chem (23-6-1995) 270, 14884-14890. PubMed Europe PubMed DOI I

1994

[YEAR:3-5-1994]Agarwala,K.L., Kawabata,S., Takao,T., Murata,H., Shimonishi,Y., Nishimura,H. and Iwanaga,S. Activation peptide of human factor IX has oligosaccharides O-glycosidically linked to threonine residues at 159 and 169 Biochemistry (3-5-1994) 33, 5167-5171. PubMed Europe PubMed DOI
[YEAR:4-2-1994]Astermark,J., Hogg,P.J. and Stenflo,J. The gamma-carboxyglutamic acid and epidermal growth factor-like modules of factor IXa beta. Effects on the serine protease module and factor X activation J Biol Chem (4-2-1994) 269, 3682-3689. PubMed Europe PubMed
Bristol,J.A., Freedman,S.J., Furie,B.C. and Furie,B. Profactor IX: the propeptide inhibits binding to membrane surfaces and activation by factor XIa Biochemistry (1994) 33, 14136-14143. PubMed Europe PubMed DOI
Lin,S.W., Lin,C.N., Hamaguchi,N., Smith,K.J. and Shen,M.C. Characterization of a factor IX variant with a glycine207 to glutamic acid mutation Blood (1994) 84, 1866-1873. PubMed Europe PubMed M
[YEAR:26-4-1994]Zhong,D., Smith,K.J., Birktoft,J.J. and Bajaj,S.P. First epidermal growth factor-like domain of human blood coagulation factor IX is required for its activation by factor VIIa/tissue factor but not by factor XIa Proc Natl Acad Sci U S A (26-4-1994) 91, 3574-3578. PubMed Europe PubMed PMC EPMC

1993

Bajaj,S.P. and Birktoft,J.J. Human factor IX and factor IXa Methods Enzymol (1993) 222, 96-128. PubMed Europe PubMed DOI V

1992

[YEAR:5-9-1992]Nishimura,H., Takao,T., Hase,S., Shimonishi,Y. and Iwanaga,S. Human factor IX has a tetrasaccharide O-glycosidically linked to serine 61 through the fucose residue J Biol Chem (5-9-1992) 267, 17520-17525. PubMed Europe PubMed

1991

[YEAR:15-6-1991]Lawson,J.H. and Mann,K.G. Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation J Biol Chem (15-6-1991) 266, 11317-11327. PubMed Europe PubMed

1990

[YEAR:5-1-1990]Lin,S.W., Smith,K.J., Welsch,D. and Stafford,D.W. Expression and characterization of human factor IX and factor IX-factor X chimeras in mouse C127 cells J Biol Chem (5-1-1990) 265, 144-150. PubMed Europe PubMed
Lozier,J.N., Monroe,D.M., Stanfield-Oakley,S., Lin,S.W., Smith,K.J., Roberts,H.R. and High,K.A. Factor IX New London: substitution of proline for glutamine at position 50 causes severe hemophilia B Blood (1990) 75, 1097-1104. PubMed Europe PubMed
Sarkar,G., Koeberl,D.D. and Sommer,S.S. Direct sequencing of the activation peptide and the catalytic domain of the factor IX gene in six species Genomics (1990) 6, 133-143. PubMed Europe PubMed DOI
[YEAR:1-1-1990]Spitzer,S.G., Warn-Cramer,B.J., Kasper,C.K. and Bajaj,S.P. Replacement of isoleucine-397 by threonine in the clotting proteinase factor IXa (Los Angeles and Long Beach variants) affects macromolecular catalysis but not L-tosylarginine methyl ester hydrolysis. Lack of correlation between the ox brain prothrombin time and the mutation site in the variant proteins Biochem J (1-1-1990) 265, 219-225. PubMed Europe PubMed PMC EPMC

1989

Ryan,J., Wolitzky,B., Heimer,E., Lambrose,T., Felix,A., Tam,J.P., Huang,L.H., Nawroth,P., Wilner,G. and Kisiel,W. Structural determinants of the factor IX molecule mediating interaction with the endothelial cell binding site are distinct from those involved in phospholipid binding J Biol Chem (1989) 264, 20283-20287. PubMed Europe PubMed
Ware,J., Diuguid,D.L., Liebman,H.A., Rabiet,M.J., Kasper,C.K., Furie,B.C., Furie,B. and Stafford,D.W. Factor IX San Dimas. Substitution of glutamine for Arg-4 in the propeptide leads to incomplete gamma-carboxylation and altered phospholipid binding properties J Biol Chem (1989) 264, 11401-11406. PubMed Europe PubMed

1987

Lin,S.W., Dunn,J.J., Studier,F.W. and Stafford,D.W. Expression of human factor IX and its subfragments in Escherichia coli and generation of antibodies to the subfragments Biochemistry (1987) 26, 5267-5274. PubMed Europe PubMed E

1985

Anson,D.S., Austen,D.E. and Brownlee,G.G. Expression of active human clotting factor IX from recombinant DNA clones in mammalian cells Nature (1985) 315, 683-685. PubMed Europe PubMed E
Chen,S.H., Yoshitake,S., Chance,P.F., Bray,G.L., Thompson,A.R., Scott,C.R. and Kurachi,K. An intragenic deletion of the factor IX gene in a family with hemophilia B J Clin Invest (1985) 76, 2161-2164. PubMed Europe PubMed DOI PMC EPMC M
Kisiel,W., Smith,K.J. and McMullen,B.A. Proteolytic inactivation of blood coagulation factor IX by thrombin Blood (1985) 66, 1302-1308. PubMed Europe PubMed

1984

Anson,D.S., Choo,K.H., Rees,D.J., Giannelli,F., Gould,K., Huddleston,J.A. and Brownlee,G.G. The gene structure of human anti-haemophilic factor IX EMBO J (1984) 3, 1053-1060. PubMed Europe PubMed PMC EPMC
Cho,K., Tanaka,T., Cook,R.R., Kisiel,W., Fujikawa,K., Kurachi,K. and Powers,J.C. Active-site mapping of bovine and human blood coagulation serine proteases using synthetic peptide 4-nitroanilide and thio ester substrates Biochemistry (1984) 23, 644-650. PubMed Europe PubMed
Fuchs,H.E., Trapp,H.G., Griffith,M.J., Roberts,H.R. and Pizzo,S.V. Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors J Clin Invest (1984) 73, 1696-1703. PubMed Europe PubMed DOI PMC EPMC
Lollar,P. and Fass,D.N. Inhibition of activated porcine factor IX by dansyl-glutamyl-glycyl-arginyl-chloromethylketone Arch Biochem Biophys (1984) 233, 438-446. PubMed Europe PubMed

1983

Link,R.P. and Castellino,F.J. Kinetic comparison of bovine blood coagulation factors IXa alpha and IXa beta toward bovine factor X Biochemistry (1983) 22, 4033-4041. PubMed Europe PubMed

1981

McRae,B.J., Kurachi,K., Heimark,R.L., Fujikawa,K., Davie,E.W. and Powers,J.C. Mapping the active sites of bovine thrombin, factor IXa, factor Xa, factor XIa, factor XIIa, plasma kallikrein, and trypsin with amino acid and peptide thioesters: development of new sensitive substrates Biochemistry (1981) 20, 7196-7206. PubMed Europe PubMed
[YEAR:10-4-1981]van Dieijen,G., Tans,G., Rosing,J. and Hemker,H.C. The role of phospholipid and factor VIIIa in the activation of bovine factor X J Biol Chem (10-4-1981) 256, 3433-3442. PubMed Europe PubMed

1980

Jackson,C.M. and Nemerson,Y. Blood coagulation Annu Rev Biochem (1980) 49, 765-811. PubMed Europe PubMed DOI

1979

Davie,E.W., Fujikawa,K., Kurachi,K. and Kisiel,W. The role of serine proteases in the blood coagulation cascade Adv Enzymol Relat Areas Mol Biol (1979) 48, 277-318. PubMed Europe PubMed

1978

Di Scipio,R.G., Kurachi,K. and Davie,E.W. Activation of human factor IX (Christmas factor) J Clin Invest (1978) 61, 1528-1538. PubMed Europe PubMed DOI PMC EPMC
[YEAR:25-3-1978]Lindquist,P.A., Fujikawa,K. and Davie,E.W. Activation of bovine factor IX (Christmas factor) by factor XIa (activated plasma thromboplastin antecedent) and a protease from Russell's viper venom J Biol Chem (25-3-1978) 253, 1902-1909. PubMed Europe PubMed

1977

Osterud,B. and Rapaport,S.I. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation Proc Natl Acad Sci U S A (1977) 74, 5260-5264. PubMed Europe PubMed PMC EPMC

1976

Fujikawa,K. and Davie,E.W. Bovine factor IX (Christmas factor) Methods Enzymol (1976) 45, 74-83. PubMed Europe PubMed DOI V